{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T13:59:21Z","timestamp":1769867961156,"version":"3.49.0"},"reference-count":26,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2023,2,28]]},"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1136\/ejhpharm-2022-003589","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T18:20:44Z","timestamp":1678386044000},"page":"450-454","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Analytical and clinical validation of an LC-MS\/MS method for carbamazepine, lamotrigine and levetiracetam in dried blood spots"],"prefix":"10.1136","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-1714","authenticated-orcid":false,"given":"Daphne den","family":"Besten-Bertholee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan J","family":"Touw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G J","family":"ter Horst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"2024123003351198000_31.5.450.1","unstructured":"National Institute for Health and Care Excellence (NICE) . Epilepsies: diagnosis and management [CG137]. 2012 (updated May 2021). Available: https:\/\/nice.org.uk\/guidance\/cg137\/chapter\/Appendix-E-Pharmacological-treatment [Accessed 16 Aug 2019]."},{"key":"2024123003351198000_31.5.450.2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Landmark","year":"2016","journal-title":"Epileptic Disord"},{"key":"2024123003351198000_31.5.450.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167433","article-title":"Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children","volume":"11","author":"Martial","year":"2016","journal-title":"PLoS One"},{"key":"2024123003351198000_31.5.450.4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.clinbiochem.2016.12.008","article-title":"Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: a step towards home sampling","volume":"50","author":"Linder","year":"2017","journal-title":"Clin Biochem"},{"key":"2024123003351198000_31.5.450.5","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.156"},{"key":"2024123003351198000_31.5.450.6","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31819e91ce"},{"key":"2024123003351198000_31.5.450.7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bcpt.13269","article-title":"Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti\u2010epileptic drugs","volume":"125","author":"Min","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2024123003351198000_31.5.450.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108190","article-title":"Clinical validation and implications of dried blood spot sampling of carbamazepine, valproic acid and phenytoin in patients with epilepsy","volume":"9","author":"Kong","year":"2014","journal-title":"PLoS One"},{"key":"2024123003351198000_31.5.450.9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4155\/bio.12.309","article-title":"Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles","volume":"5","author":"Wickremsinhe","year":"2013","journal-title":"Bioanalysis"},{"key":"2024123003351198000_31.5.450.10","doi-asserted-by":"publisher","DOI":"10.4155\/bio.11.132"},{"key":"2024123003351198000_31.5.450.11","unstructured":"Clinical and Laboratory Standards Institute (CLSI) . Blood collection on filter paper for newborn screening programs; approved standard. 2013."},{"key":"2024123003351198000_31.5.450.12","unstructured":"US FDA . Guidance for industry: bioanalytical method validation. 2001: 4\u201310."},{"key":"2024123003351198000_31.5.450.13","doi-asserted-by":"publisher","DOI":"10.1155\/S1463924685000177"},{"key":"2024123003351198000_31.5.450.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"2024123003351198000_31.5.450.15","unstructured":"European Medicines Agency . Guideline on bioanalytical method validation. 2011. Available: https:\/\/ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf"},{"key":"2024123003351198000_31.5.450.16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/21548331.2017.1296318","article-title":"Determination of serum carbamazepine concentration using dried blood spot specimens for resource-limited settings","volume":"45","author":"Das","year":"2017","journal-title":"Hosp Pract (1995)"},{"key":"2024123003351198000_31.5.450.17","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.4155\/bio.15.99","article-title":"A LC-MS\/MS method for therapeutic drug monitoring of carbamazepine, lamotrigine and valproic acid in DBS","volume":"7","author":"Linder","year":"2015","journal-title":"Bioanalysis"},{"key":"2024123003351198000_31.5.450.18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2017.11.005","article-title":"Carbamazepine, lamotrigine, levetiracetam and valproic acid in dried blood spots with liquid chromatography tandem mass spectrometry; method development and validation","volume":"1072","author":"Linder","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2024123003351198000_31.5.450.19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/bcp.14249","article-title":"Effects, costs and implementation of monitoring kidney transplant patients\u2019 tacrolimus levels with dried blood spot sampling: a randomized controlled hybrid implementation trial","volume":"86","author":"Veenhof","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2024123003351198000_31.5.450.20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2024123003351198000_31.5.450.21","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.185"},{"key":"2024123003351198000_31.5.450.22","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4155\/bio.13.170","article-title":"The effect of hematocrit on bioanalysis of DBS: results from the EBF DBS-microsampling consortium","volume":"5","author":"de Vries","year":"2013","journal-title":"Bioanalysis"},{"key":"2024123003351198000_31.5.450.23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpba.2018.10.010","article-title":"Is the hematocrit still an issue in quantitative dried blood spot analysis?","volume":"163","author":"Velghe","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"2024123003351198000_31.5.450.24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1515\/cclm-2019-1260","article-title":"Volumetric absorptive microsampling and dried blood spot microsampling vs. conventional venous sampling for tacrolimus trough concentration monitoring","volume":"58","author":"Veenhof","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2024123003351198000_31.5.450.25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FTD.0000000000000890","article-title":"Therapeutic drug monitoring of lamotrigine, lacosamide, and levetiracetam in dried capillary blood - determination of conversion factors for serum-based reference ranges","volume":"43","author":"Klimpel","year":"2021","journal-title":"Ther Drug Monit"},{"key":"2024123003351198000_31.5.450.26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpba.2016.06.026","article-title":"Clinical feasibility of dried blood spots: analytics, validation, and applications","volume":"130","author":"Enderle","year":"2016","journal-title":"J Pharm Biomed Anal"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2022-003589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:36:44Z","timestamp":1735558604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2022-003589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/ejhpharm-2022-003589"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2022-003589","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}